Skip to main content

Table 3 Literature-based Recommendations for Improvement of Inputs to Existing Frameworks

From: Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Suggested improvement

No of Articles

References

Need improvements to clinical trial design to obtain more patient-relevant data

5 of 17 (29%)

[102, 110, 112, 115, 119]

Need cost data that reflect full cost of care/treatment (not just drug costs)

5 of 17 (29%)

[104, 108, 112, 116, 117]

Frameworks should incorporate patient-reported outcome data (via inclusion of patient-reported outcomes in clinical trials)

4 of 17 (24%)

[103, 112, 119, 138]

Frameworks should incorporate data from sources other than clinical trials (e.g., observational studies)

3 of 17

(18%)

[102]

Frameworks should incorporate more robust and/or detailed safety and/or toxicity data

7 of 17

(41%)

[103, 104, 108, 112, 115, 116]

Frameworks should use integrated quality of life measures in lieu of safety data

1 of 17

(6%)

[117]

Frameworks should incorporate more longitudinal data

2 of 17

(12%)

[102, 103]

Frameworks should engage patients in the data evaluation and input process

3 of 17

(18%)

[102, 103, 110]